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The design of glycoconjugates to allow the generation of multivalent ligands capable of interacting with 
the receptor DC-SIGN is a topic of high interest due to the role played by this lectin in pathogen 
infections. Mannose, a ligand of this lectin, could be conjugated at two different positions, 1 and 6, not 
implicated in the binding process. We have prepared mannose conjugates at these two positions with a 
long spacer to allow their attachment to a biosensor chip surface. Analysis of the interaction between 
these surfaces and the tetravalent extracellular domain (ECD) of DC-SIGN by SPR biosensor has 
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demonstrated that both positions are available for this conjugation without affecting the protein binding 
process. These results emphasize the possibility to conjugate mannose at position 6 allowing the 
incorporation of hydrophobic groups at the anomeric position to interact with hydrophobic residues in 
the carbohydrate recognition domain of DC-SIGN increasing binding affinities. This fact is relevant for 
the future design of new ligands and the corresponding multivalent systems for DC-SIGN. 
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INTRODUCTION 
 
Carbohydrate-protein interactions are involved in several cell adhesion and cell communication 
processes that govern basically the social behavior of cells. Inflammation, (1) tumor progression and 
metastasis, (2) cell development and embryogenesis, (3) infection (4) are some of the important 
biological events where carbohydrates play a key role through the interaction with their corresponding 
protein receptors. (5-6) These carbohydrate interactions are highly selective, calcium dependent and 
very weak. (7) Nature has overcome this problem with a multivalent presentation of carbohydrate 
epitopes such as glycosphingolipid clustering into lipid rafts and presentation of multiple copies of 
carbohydrates on glycoproteins.  Therefore the design and development of chemical tools to understand 
and intervene into these processes involving carbohydrates require the appropriate multivalent scaffolds 
that can be functionalized with selected carbohydrates. (8-10) 
Our research interest has been focused during the last years on a lectin named DC-SIGN (Dendritic 
Cell-Specific ICAM-3 Grabbing Non-integrin) or CD209. This C-type lectin is expressed at the surface 
of immature dendritic cells and presents at its C-terminus a Carbohydrate Recognition Domain (CRD). 
(11-12) Recognition of pathogens by dendritic cells takes place through an interaction involving 
glycosylated proteins at the surface of pathogens and the receptor DC-SIGN. (13-16) This recognition 
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process is one of the first steps in a complex pathway of events controlled by the immune system. 
Previous work of our laboratory has demonstrated that multivalent systems based on mannose as 
carbohydrate and hyperbranched dendritic polymer Boltorn as multivalent scaffold are capable to 
interact with DC-SIGN and inhibit the infection process of a pseudotyped viral particle that express the 
GP1 glycoprotein of Ebola virus. (17-19) 
Functionalization of mannose to create these glycodendritic polymers was performed at the anomeric 
position. This election was based on two main reasons. First of all, the hydroxyl groups of mannose 
implicated on binding with C type lectins are those presented at positions 2, 3 and 4. (20) Second, the 
easiest position to functionalize carbohydrates generating glycoconjugates is the anomeric position. 
Position 6 could be considered as another possibility to be functionalized taking into account that this 
hydroxyl group is well differentiated from the others (it is the only primary hydroxy group on the 
sugars) and also, it does not seem to participate in the recognition process by the C-type lectin. (21)  
Moreover, introducing hydrophobic residues at the anomeric position such as aromatic rings can 
improve the binding affinities of mannoses due to non-covalent van der Waals contacts with amino acid 
residues of a hydrophobic pocket present at the carbohydrate recognition domain of the lectin. (22-23) 
As it has been proved previously in several examples, aryl mannopyranosides show higher binding 
affinities than the corresponding mannose with a free anomeric position. (24-27) This fact could also be 
applied for DC-SIGN presenting this hydrophobic pocket and it would mean a considerable increase of 
mannose binding affinity. Depending on the residues introduced at the anomeric position, in some 
cases it could be necessary to conjugate these mannose derivatives at a different position than the 
anomeric one, mainly at position 6 of the mannose. 
To prove that functionalization of mannose position 6 with a linker will not interfere in the binding 
process with DC-SIGN, we have prepared two mannose conjugates with a linker at position 6 and 
position 1 (anomeric) respectively. We have studied the binding process of these mannoses with the 
tetrameric extracellular domain (ECD) of DC-SIGN using a biosensor with surface plasmon resonance 
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(SPR) detection. The glycoconjugates were prepared using a selected linker long enough to allow the 
attachment of these molecules to the biosensor chip surface without interfering in the binding process 
with the lectin.  This biosensor is a very useful technique that provides quantitative analysis of binding 
processes in flow conditions using a tiny amount of ligands and receptors without any label. (28) 
Biosensor has been previously succesfully used to measure binding affinities of carbohydrate ligands 
with lectins. (29-34) In fact, a comparison of these binding affinities provides a rapid method to 
evaluate the best ligands for a specific receptor. 
The mannose conjugates and the corresponding control surfaces have been used with a biosensor with 
SPR detection and the analysis of the sensorgrams have demonstrated that both positions (1 and 6) of 
mannose were adequate to create glycoconjugates that can be used as monomers to prepare the 
corresponding multivalent systems. 
 
MATERIALS AND METHODS 
Materials 
All purchased chemicals were used without further purification. Synthetic compounds were purified 
by flash chromatography using medium or fine silica gel. Reaction completion was observed by TLC 
using as development reagents phosphomolibdic acid, 10% sulfuric acid in methanol or anisaldehyde. 
1H and 13C NMR were recorded on Bruker Avance DPX 300, and DRX 500 MHz spectrometers. 
Chemical shift are in ppm with respect to TMS (Tetramethylsylane) using manufacturer indirect 
referencing method. IR spectra were recorded on a Bruker Vector 22. Optical rotations were measured 
with a Perkin-Elmer 341 polarimeter. Mass Spectra were carried out with an Esquire 6000 ESI-Ion Trap 
from Bruker Daltonics. Methyl α-D-mannopyranoside (7) and 4,7,10-trioxa-1,13-tridecanediamine (5) 
were purchased from Aldrich. 
Fmoc-protected mannose derivative with a linker at position 1 (5) 
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To a solution of 4 (18 mg, 0.088 mmol) and 7 (50 mg, 0.092 mmol) in DMF (3 mL) were added 
diisopropylcarbodiimine (DIC) (27 µL, 0.18 mmol) and hydroxybenzotriazol (HOBT) (24 mg, 0.18 
mmol). The reaction mixture was stirring at 60 ºC during 24 hours, and then evaporated.   The final 
product was purified first by sephadex LH-20 (eluent: CH2Cl2-MeOH, 1:1) to eliminated the HOBT and 
later by silica gel column chromathography (eluent: CH2Cl2-MeOH, 9:1) to give 5 as a sirup (37 mg, 66 
%). [α]D  (MeOH, c. 0.46) = + 21.78;  1H NMR (CD3OD, 500 MHz) δ(ppm)  7.77 (d, 2H, J=7.5 Hz, 
CHArFmoc), 7.62 (d, 2H, J=7.5 Hz, CHArFmoc), 7.36 (t, 2H, J=7.5 Hz, CHArFmoc), 7.28 (d, 2H, J=7.5 Hz, 
CHArFmoc), 4.72 (d, 1H, J=2.0 Hz, H1), 4.34 (d, 2H, J=6.5 Hz, CH2Fmoc), 4.17 (t, 1H, J=6.5 Hz, CHFmoc), 
3.81 (dd, 1H, J=2.0 & 11.7 Hz, H6), 3.78 (dd, 1H, J=1.5 & 3.0 Hz, H2), 3.75-3.63 (m, 4H, H3 + H4 + 
H6’ + H7), 3.63-3.45 (m, 14H, 6 x –CH2O-, H7’, H5), 3.42-3.35 (m, 1H, H8), 3.34-3.29 (m, 1H, H8), 3.20 
(t. 2H, J=6.5 Hz, CH2NH-), 3.17 (t. 2H, J=6.5 Hz, CH2NH-), 2.55-2.39 (m, 4H, -HNOC-
CH2CH2CONH-), 1.74-1.66 (m, 4H, 2 x -HNCH2CH2CH2O-); 13C NMR (CD3OD, 125 MHz) δ(ppm)  
173.4 (C=O), 173.1 (C=O), 144.0 (CArFmoc), 141.2 (CArFmoc), 127.4 (CArFmoc), 126.7 (CArFmoc), 124.7 
(CArFmoc), 119.5 (CArFmoc), 100.3 (C1), 73.4 (C5), 71.1 (C3), 70.7 (C2), 70.1, 69.8, 68.5, 68.3, 67.3 (-
CH2-O- + C4) 66.1 (CH2Fmoc), 65.8 (C7), 61.6 (C6), 38.9 (C8), 37.7 (CH2NH-), 36.5 (CH2NH-), 30.9 
(N(O)C-CH
  2), 30.8 (N(O)C-CH  2), 29.4 (-NH-CH2CH2CH2O-), 29.0 (-NH-CH2CH2CH2O-);  ESI-MS 
for C37H53N3O13 : calcd,  747,4; found,  770.4 (M + Na)+ ,786.3 (M +K)+ 
Mannose derivative with a linker at position 1 (1) 
5 (7 mg, 9.36 x 10-3 mmol) was dissolved in DMF (1 mL) then, piperidine 20% in DMF (200 µL) was 
added and the reaction was stirred during 2 hours. Then, the solvent was removed under low pressure. 
The residue was dissolved in water (10 mL) and washed with CH2Cl2 (10 mL). The water was 
eliminated under reduce pressure to give the desired product 1 as an oil (4 mg, 80%). [α]D  (MeOH, c. 
0.3) = + 23.20;  1H NMR (CD3OD, 500 MHz) δ(ppm)  4.73 (d, 1H, J=1.7 Hz, H1), 3.81 (dd, 1H, J= 2.0 
Hz & 11.5 Hz, H6’),  3.78 (dd, 1H, J= 1.7 Hz & 3.5 Hz, H2), 3.74-3.71 (m, 1H, H7’), 3.71-3.46 (m, 17 
H, H7, H6, H4, H5, H3 & 6x CH2O-), 3.46-3.37 (m, 1H, H8), 3.35-3.29 (m, 1H, H8’),  3.22 (t, 1H, J=7.0 
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Hz, CH2NH), 3.08 (t, 1H, J=6.5 Hz, CHNH), 2.49-2.43 (m, 4H, -HNOC-CH2CH2CONH-), 1.79-1.64 
(m, 4H, 2 x -HNCH2CH2CH2O-); 13C NMR (CD3OD, 125 MHz) δ(ppm) 173.4 (C=O), 173.1 (C=O), 
100.3 (C1), 73.4 (C5), 71.9, 70.8, 70.1, 70.0, 69.7, 69.6, 69.0, 68.3, 67.3 (6 x CH2O, C2, C3, C4), 65.8 
(C7), 61.5 (C6), 38.9 (C8), 38.8 (CH2NH-), 38.3 (CH2NH-), 30.7 (N(O)C-CH  2), 30.6 (N(O)C-CH  2), 29.3 
(-NH-CH2CH2CH2O-), 29.3 (-NH-CH2CH2CH2O-); ESI-MS for C22H43N3O11: calcd,  525,3; found, 
526.3 (M + H)+   
α-Methyl 6-tosyl mannopyranoside (9) (35) 
α-Methyl mannopyranoside (8) (2.0 g, 10.30 mmol) was dissolved in dry pyridine (30 mL) and cooled 
to 0º C. Then, tosyl chloride (2.77, 14.53 mmol) was slowly added. The reaction was kept stirring at 0º 
C over night. The solvent was removed under reduced pressure, and the residue was purified by flash 
chromatography with silica gel (eluent: Hex-AcOEt, 7:1) to afford the desired product (5.1 g, 70% 
yield) as a white solid. [α]D  (CHCl3, c. 1.00) = + 47.3;  1H NMR (CDCl3, 300 MHz) δ(ppm) 7.80 (d, 
2H, J=8.3 Hz, 2H Ts), 7.33 (d, 2H, J=2H, J=8.0 Hz, 2H Ts), 4.67 (d, 1H, J=1.2 Hz, H1), 4.35(dd, 1H, 
J=10.7 & 4.1 Hz, H6), 4.26 (dd, 1H, J= 4 Hz &  10.7 Hz, H6), 3.95-3.87 (m, 1H, H2), 3.78-3.62 (m, 3H, 
H3 + H4 + H5), 3.30 (s, 3H, -OCH3), 2.42 (s, 3H, CH3-Ar); 13C NMR (CDCl3, 125 MHz) δ(ppm) 145.0 
(CTs), 132.7 (CTs), 129.9 (CHTs), 128.0 (CHTs), 100.9 (C1), 71.6 (C3), 70.5 (C2), 69.8 (C4), 69.1 (C6), 
67.3 (C5), 55.2(-OCH3), 21.7 (-CH3Ts); ESI-MS for C14H20O8S: calcd, 348.1; found, 386.9 (M + K)+ 
α-Methyl 6-azido-6-deoxy- mannopyranoside (10) 
A mixture of α-Methyl 6-tosyl mannopyranoside (9) (2.8 g, 8.04 mmol) and sodium azide (4.18 g, 
64.35 mmol) in dry DMF (40 mL) was stirred at 60 ºC overnight.  After the reaction was complete, the 
solvent was removed in vacuo and the residue was dissolved in ethyl acetate. The excess of sodium 
azide and sodium tosylate was removed by filtration and the filtrate was evaporated and purified by 
flash chromatography (eluent: DCM-MeOH, 9.5:0.5) to afford 9 as an oil (1.52 g, 98% yield). [α]D 
(MeOH, c. 1.00) = + 54.80; 1H NMR (CD3OD, 500 MHz) δ (ppm) 4.62 (d, 1H, J=1.4 Hz, H1), 3.77 
(dd, 1H, J=1.6 Hz & 3.2 Hz, H2), 3.60 (dt, 1H, J=3.3 Hz & 9.3 Hz, H3), 3.61-3.56 (m, 1H, H5) 3.54 (c, 
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1H, J=9.3 Hz, H4), 3.45 (dd, 1H, J=2.2 Hz & 12.9 Hz, H6), 3.43 (dd, 1H, J= 6.0 Hz & 12.9 Hz, H6) 
3.38 (s, 3H, -OCH3); 13C NMR (CD3OD, 125 MHz) δ (ppm) 101.5 (C1), 72.3 (C5), 71.0 (C3), 70.6 (C2), 
68.1 (C4), 53.9 (C6), 51.5 (-OCH3); ESI-MS for C7H13N3O5: calcd, 219.1; found,  242.0 (M + Na)+ 
α-Methyl 6-amino-6-deoxy- mannopyranoside (11) 
 α-Methyl 6-azido-6-deoxy mannopyranoside (10) (130 mg, 0.59 mmol) was disolved in MeOH (30 
mL). Pd-C 10% (cat) was added and the reaction mixture was saturated with hydrogen (1 bar) until 
reduction was complete to give 11 (120 mg, quant.) as a white solid. [α]D (MeOH, c. 100) = + 49.3; 1H 
NMR (CD3OD, 300 MHz) δ(ppm) 4.67 (d, 1H, J=1.1 Hz, H1), 3.84-3.74 (m, 1H, H2),  3.71-3.63 (m, 
1H, H3) 3.60-3.45 (m, 2H, H4 & H5), 3.40 (s, 3H, -OCH3), 3.13 (d, 1H, J=12 Hz, H6), 2.95 (dd, 1H, J=6 
Hz & 13.2 Hz, H6); 13C NMR (CD3OD, 75 MHz) δ(ppm) 102.9 (C1), 72.7 (C4), 72.3 (C3), 72.0 (C2), 
69.7 (C5), 55.5 (-OCH3), 43.0 (C6); ESI-MS for C7H15NO5: calcd, 193.1; found, 194.0 (M + H)+ and 
220.0 (M + Na)+  
Fmoc-protected mannose derivative with a linker at position 6 (12) 
To a solution of 11 (33 mg, 0.175 mmol) and 7 (100 mg, 0.092 mmol) in DMF (7 mL) were added DIC 
(60 µL, 0.35 mmol) and HOBT (47 mg, 0.35 mmol). The reaction mixture was stirring at 60 ºC during 
24 hours, and then the solvent was removed under low pressure.   The final product was purified first by 
sephadex LH-20 (eluent: CH2Cl2-MeOH, 1:1) to eliminated the HOBT and later by silica gel column 
chromatography (eluent: CH2Cl2-MeOH, 95:5) to give 12 (75 mg, 60 %) as a syrup. [α]D  (MeOH, c. 
1.00) = + 19.02; 1H NMR (CD3OD, 300 MHz) δ(ppm) 7.81 (d, 2H, J=7.5 Hz, CHArFmoc), 7.66 (d, 2H, 
J=7.2 Hz, CHArFmoc), 7.43 (t, 2H, J=7.5 Hz, CHArFmoc), 7.32 (t, 2H, J=7.5 Hz, CHArFmoc), 4.62 (d, 1H, 
J=1.5 Hz, H1), 4.38 (d, 2 H, J=6.6 Hz, CH2Fmoc), 4.21 (t, 1 H, J=6.3 Hz, CHFmoc), 3.80 (dd, 1H, J=1.8 & 
3.3 Hz), 3.72-3.45 (m, 17H, 6 x -CH2-O- + H3 + H4 + H5 + 2H6), 3.35 (s, 3H, -OCH3), 3.29-3.17 (m, 
4H, 2 x CH2NH-), 2.56-2.44 (m, 4H, 2 x N(O)C-CH2), 1.80-1.69 (m, 4H, 2 x -NH-CH2CH2CH2O-); 13C 
NMR (CD3OD, 75 MHz) δ (ppm) 175.1 (C=O), 174.5 (C=O), 145.3 (CArFmoc), 142.6 (CArFmoc), 128.7 
(CHArFmoc), 128.1 (CHArFmoc), 126.1 (CHArFmoc), 121.9 (CHArFmoc), 102.8 (C1), 72.4,  72.2, 72.1, 71.5, 
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71.2, 69.8, 69.7, 69.4 ((-CH2-O- + C2 + C3 + C4 + C5), 67.5 (CH2Fmoc), 55.3 (C6), 48.5 (CHFmoc), 41.3 
(CH2NH-), 39.1 (CH2NH-), 37.9 (CH2NH-), 32.3 (N(O)C-CH2), 32.2 (N(O)C-CH2), 30.8 (-NH-
CH2CH2CH2O-), 30.3 (-NH-CH2CH2CH2O-); ESI-MS for C36H51N3O12: calcd, 717.3; found, 740.3 (M 
+ Na)+ and 756.3 (M + K)+  
Mannose derivative with a linker at position 6 (2) 
12 (25 mg, 0.035 mmol) was dissolved in DMF (2 mL). Piperidine 20% in DMF (400 µL) was added 
and the reaction was stirred during 2 hours. Then, the solvent was evaporated. The residue was disolved 
in water (20 mL) and washed with CH2Cl2 (20 mL). The water was eliminated under reduce pressure to 
give the desired product 2 as an oil (17 mg, quant). [α]D  (MeOH, c. 1.00) =  + 20.9;  1H NMR 
(CD3OD, 300 MHz) δ(ppm) 4.63 (d, 1H, J=1.8 Hz, H1),  3.80 (dd, 1H, J=1.8 Hz & 3.6 Hz, H2), 3.70-
3.56 (m, 13H, H3, H5, H4, 5 x -CH2-O- ) 3.56-3.48 (m, 6H, 2H6, -CH2-O-), 3.37 (s, 3H, -OCH3), 3.27 (t, 
2 H, J= 6.9 Hz, CH2NH-),  2.85 (t, 2H, J=6.9 Hz, CH2NH-), 2.57-2.44 (m, 4H, 2 x N(O)C-CH2), 1.86-
1.71 (m, 4H, 2 x -NH-CH2CH2CH2O-); 13C NMR (CD3OD, 75 MHz) δ(ppm) 175.1 (C=O), 174.6 
(C=O), 102.8 (C1), 72.4, 72.2 , 72.1, 71.5, 71. 4, 71.2, 71.1, 70.4, 69.8, 69.4 (C2, C3, C4, C5, 6 x -CH2-
O-
 
 ), 55.3 (-OCH3),  41.3 (C6), 40.1 (CH2NH-), 37.8 (CH2NH-), 32.3 (N(O)C-CH2), 32.1 (N(O)C-
CH2), 31.9 (C CH2CH2CH2O-), 30.4 (C CH2CH2CH2O-); ESI-MS for C21H41N3O10: calcd, 495; found,  
496.3 (M + H)+ 
Fmoc-protected 4,7,10-trioxa-1,13-tridecanediamine succinimic acid (7) (36) 
4,7,10-Trioxa-1,13-tridecanediamine (6) (1.11 g, 5.045 mmol) was disolved in acetonitrile (25 mL) and 
succinic anhydride (0.5 g, 5.045 mmol) in acetonitrile (12.5 mL) was added slowly over 1 hour. The 
reaction was stirred at room temperature for 3 additional hours. Then, the organic layer was decanted 
and the waxy oil was re-dissolved in 50% aqueous acetonitrile (50 mL) and cooled at 0ºC for one hour 
and then, 1.3 equivalents of Fmoc-OSu (2.2 g, 6.52 mmol) in acetonitrile (12.5 mL) were added slowly 
together with diisopropylethylamine to maintain pH 8-9. After stirring overnight at room temperature, 
solvents were removed under low pressure and the residue was dissolved in 5% NaHCO3 (50 mL) and 
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washed with AcOEt. The organic layer was discarded and the aqueous phase was acidified to pH 2 with 
5% HCl. Then, the aqueous phase was extracted with AcOEt (3 x 25 mL). The combined organic layers 
were dried (Na2SO4) and the solvent was evaporated to give 7 (1.8 g, 66%). 1H NMR (CD3OD, 500 
MHz)  δ (ppm) 7.77 (d, 1H, J= 7.5 Hz, CHArFmoc),  7.62 (d, 1H, J= 7.5 Hz, CHArFmoc), 7.36 (d, 1H, J= 
7.5 Hz, CHArFmoc), 7.28 (d, 1H, J= 7.5 Hz, CHArFmoc), 4.34 (d, 2H, J= 7.0 Hz, CH2Fmoc), 4.17 (t, 1H, J= 
6.5 Hz, CHFmoc), 3.62-3.42 (m, 12H, 6 x CH2O-),  3.21 (t, 2H, J=6.5 Hz, ), 3.16 (t, 2H, J= 6.5 Hz, ) 
2.53 (t, 2H, J= 6.7 Hz, N(O)C-CH2), 2.41 (t, 2H, J= 6.7 Hz, N(O)C-CH2), 1.75-1.66 (m, 2 x -NH-CH2-
CH2-CH2-O-, ); 13C NMR (CD3OD, 125 MHz) δ (ppm) 175.9 (C=O), 159.7 (C=O), 146.2 (CArFmoc),  
143.5 (CArFmoc), 129.6 (CArFmoc), 129.0 (CArFmoc),  127.0 (CArFmoc), 121.8 (CArFmoc), 72.4 (CH2-O), 72.0 
(CH2-O), 70.7 (CH2-O), 70.6 (CH2-O), 68.3 (CH2-O), 39.9 (CH2-NH), 38.6 (CH2-NH), 33.5 (N(O)C-
CH2), 32.9 (N(O)C-CH2), 31.6 (-NH-CH2-CH2-CH2-O-), 31.2 (-NH-CH2-CH2-CH2-O-); ESI-MS for 
C29H38N2O8: calcd, 542.3; found,  543.3  (M + H)+, 565.3 (M + Na)+, and 581.2 (M + K)+ 
Fmoc-protected linker ethanol amine (13) 
To a solution of 2-aminoethanol (5.5 µL, 0.092 mmol) and 7 (50 mg, 0.092 mmol) in DMF (4 mL) 
were added DIC (29 µL, 0.184 mmol) and HOBT (25 mg, 0.184 mmol). The reaction mixture was 
stirring at 60 ºC during 24 hours, and then the solvent was evaporated. The final product was first 
purified by sephadex LH-20 (eluent: CH2Cl2-MeOH, 1:1) to eliminated the HOBT and later by silica 
gel column chromatography (eluent: CH2Cl2-MeOH, 95:5) to give 13 (34 mg, 64 %) as a syrup. 1H 
NMR (CD3OD, 500 MHz) δ(ppm) 7.77 (d, 2H, J=7.5 Hz, CHArFmoc), 7.62 (d, 2H, J=7.5 Hz, 
CHArFmoc), 7.38 (t, 2H, J=7.5 Hz, CHArFmoc), 7.28 (t, 2H, J=7.5 Hz, CHArFmoc), 4.34 (d, 2 H, J=6.5 Hz, 
CH2Fmoc), 4.17 (t, 1 H, J=6.5 Hz, CHFmoc), 3.65-3.50 (m, 12 H, -CH2-O-), 3.46 (m, 4 H, -NH-
CH2CH2CH2O-), 3.26 (t, 2H, J=5.5 Hz, CH2NH-), 3.20 (t, 2H, J=6.5 Hz, CH2NH-), 3.16 (t, 2H, J=5.5 
Hz, CH2NH-), 2.47-2.41 (m, 4 H, N(O)C-CH2) 1.73-1.71 (m, 4 H, -NH-CH2CH2CH2O-). 13C NMR 
(CD3OD, 125 MHz) δ(ppm) 173.5 (C=O), 173.1 (C=O), 144.0 (CArFmoc), 141.2 (CArFmoc), 127.4 
(CHArFmoc), 126.7 (CHArFmoc), 124.7 (CHArFmoc), 119.5 (CHArFmoc), 70.1 (-CH2-O-), 69.8 (-CH2-O-), 
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68.5 (-CH2-O-), 68.3 (-CH2-O-), 66.1 (CH2Fmoc), 60.2 (-CH2-OH), 47.2 (CHFmoc), 41.6 (CH2NH-), 37.7 
(CH2NH-),  36.4 (CH2NH-), 30.9 (2 x N(O)C-CH2), 29.4 (-NH-CH2CH2CH2O-), 29.0 (-NH-
CH2CH2CH2O-). ESI-MS for C31H43N3O8: calcd, 585.3; found, 608.3 (M + Na)+ and 624.2 (M + K) + 
Linker ethanol amine (3) 
13 (10 mg, 0.017 mmol) was dissolved in DMF (2 mL) and 20% of piperidine in DMF (400 µL) was 
added. The reaction was stirred during 2 hours. Then, the solvent was evaporated. The residue was 
dissolved in water (10 mL) and washed with CH2Cl2 (10 mL). The water was eliminated under reduce 
pressure to give the desired product 3 as an oil (6 mg, quant). 1H NMR (CD3OD, 500 MHz) δ (ppm) 
3.65-3.50 (m, 12H, 5 x -CH2O- + -CH2OH), 3.49 (t, 2H, J= 6.0 Hz, -CH2O-),  3.26 (t, 2H, J= 6.5 Hz, -
CH2NH), 3.22 (t, 2H, J= 6.5 Hz, -CH2NH), 2.86 (t, 2H, J= 6.5 Hz, -CH2NH),  2.46-2.43 (m, 4H, 2 x 
N(O)C-CH2),  1.79 (q, 2H, J= 6.0 Hz, 2 x -NH-CH2CH2CH2O-), 1.72 (q, 2H, J= 6.0 Hz, 2 x -NH-
CH2CH2CH2O-); 13C NMR (CD3OD, 125 MHz) δ (ppm) 173.5 (C=O), 173.2 (C=O), 70.1, 70.0, 69.8, 
69.7, 69.0, 68.4, 60.2 (6 x –CH2O + -CH2OH), 41.6 (CH2NH-), 38.7 (CH2NH-), 36.4 (CH2NH-), 30.8 
(N(O)C-CH2), 30.8 (N(O)C-CH2), 29.8 (CH2CH2CH2O-), 29.0 (CH2CH2CH2O-); ESI-MS for 
C16H33N3O6: calcd, 363.2; found,  386.2  (M + Na)+  
     
DC-SIGN ECD expression and purification. 
Plasmids pET30b (Novagen) containing a cDNA encoding the ExtraCellular-Domain of DC-SIGN 
(DC-SIGN ECD corresponding to aminoacids 66-404) were used for protein overproduction as 
previously described. (29) Proteins produced in inclusion bodies have been refolded as already 
described. (12) Purification of functional DC-SIGN proteins were achieved by an affinity 
chromatography on Mannan-agarose column (Sigma) equilibrated with 25 mM Tris-HCl pH 7.8, 150 
mM NaCl, 4 mM CaCl2 (Buffer A) and eluted in same buffer lacking CaCl2 but supplement with 10 
mM EDTA. This step was followed by a Superose 6 size exclusion chromatography (Amersham) 
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equilibrated in buffer A. Proteins were concentrated,  frozen in liquid Nitrogen and stored at minus 
80°C. 
Biosensor experiments 
Experiments have been conducted on a BIAcore 3000 instrument. Lyophilized compounds 1, 2 and 
3 have been solubilised in HBS-N buffer reagent from BIAcore. These derivatives have then been used 
for functionalization of a CM5 chips (BIAcore). Flow cells were activated with a 50µl injection of an 
EDC-NHS mixture as described by manufacturer and blocked, after functionalization, with 50µL of 1 
M ethanolamine. Flow cell one (control flow cell), two and three were functionalized with 70 µL of 
control compound 3, mannose conjugate compound 2 and mannose conjugate compound 1 diluted at 
50 µM in 10 mM acetate buffer pH 4, respectively. The corresponding immobilization levels were of 
793, 961, 848 RU for the flow cell one, two and three, respectively. 
For binding studies, 50 µL of DC-SIGN ECD, in running buffer A supplemented in 0.005 % P20 
surfactant, were injected, at a flow rate of 20µL.min-1, onto the functionnalized surfaces at increasing 
concentrations. 
RESULTS AND DISCUSSION 
Synthesis of glycoconjugates 
The 2-aminoethyl α-D-mannopyranoside (4) has been previously prepared in our laboratory and was 
used as starting material to prepare the mannose conjugated functionalized at position 1. We have 
considered that a longer linker should be more adequate to allow its attachment to the biosensor chip 
surface. For this reason, mannose derivative 4 was conjugated with linker 7 via an amide bond 
formation to obtain the glycoconjugate 1 with a longer spacer, after Fmoc removal. Linker 7 was 
prepared in two steps as described in the literature (36) from commercially available 4,7,10-trioxa-1,13-
tridecanediamine (6) by reaction with succinic anhydride and subsequent amine protection as 
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carbamate with N-(9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSu). (Scheme 1) Reaction of 
2-aminoethyl α-D-mannopyranoside (4) with linker 7 in the presence of DIC and HOBt at 60ºC gave 
selectively the mannose derivative 5 with an amide linkage in 66 % yield. Using these conditions was 
not necessary to protect the mannose hydroxyl groups. After this coupling, the Fmoc protecting group 
was easily removed by treatment with 20% of piperidine in DMF at room temperature to give in 80% of 
yield compound 1, the mannosyl glycoconjugate functionalized at position 1. (Scheme 1) 
  
Scheme 1. Synthesis of mannose derivative 1 functionalized at the anomeric position and synthesis of 
linker 7. 
To prepare a mannose derivative functionalized at position 6 we used as starting material the 
commercially available methyl α-D-mannopyranoside (8). To use the same type of linkage that used 
with mannose derivative 4 we decided to introduce a primary amine at position 6 of the mannose. The 
6-deoxy-6-amino mannose derivative 11 was prepared in three steps using the methodology described 
(35) introducing some modifications. We converted the 6-hydroxyl group in a good leaving group by 
reaction with tosyl chloride at 0ºC in pyridine using the procedure described in the literature (35) to 
gave the mannose derivative 9 in 70% of yield. Then, the tosyl group was substituted by an azide group 
by reaction with an excess of sodium azide in DMF. We tried the conditions previously described (35) 
to substitute the tosyl group by azide in a mixture acetone-water (3-2) under reflux but the attempts 
using these conditions were fruitless recovering the starting material in all the cases. Using DMF as 
solvent at 60ºC, the reaction was complete overnight to yield the methyl-6-deoxy-6-azido 
mannopyranoside (10) in 98% of yield. The last step to get the amine group at position 6 was the 
catalytic hydrogenation of azide group using Pd/C at 1 atm of H2 to obtain the methyl 6-deoxy-6-amino 
mannopyranoside (11) in quantitative yield. (35) (Scheme 2) 
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Scheme 2. Synthesis of mannose conjugate 2. 
Once the mannose derivative 11 was obtained, the coupling with the linker 7 was performed using 
the same conditions that those used with mannose derivative 4, DIC, HOBt in DMF at room 
temperature to give the glycoconjugate 12 in 60% of yield with the linker at the anomeric position. 
Again, the last step was the removal of Fmoc protecting group with 20% of piperidine in DMF at room 
temperature to obtain mannose conjugate 2 in quantitative yield. (Scheme 2) 
Finally, a control for the binding studies was prepared. We used the same spacer 7 coupled with 
ethanol amine using DIC and HOBt in DMF at 60ºC to give the compound 13 in 64% of yield. Again, 
deprotection of amine group with 20% of piperidine in DMF at room temperature gave compound 3 in 
quantitative yield which will be used as control. (Scheme 3). 
 
Scheme 3. Synthesis of control compound 3. 
Surface functionalization 
In our mannose derivatives, the spacer added on position 6 or 1 have been designed with an amine 
terminal group. This function will allow further chemistry assembly in order to produce future 
multivalent dendrimeric compounds. But this extremity can also be considered here as a mimics of a 
Lysine side chain and may be used to functionnalised the SPR surfaces using N-hydroxysuccinamide 
and EDC chemistry as usually done to covalently link proteins. Such protein functionalization methods 
lead to covalent attachment of the lysine residue to the carboxylic groups harbored by the dextran 
polymer present at the sensorchip surface. Similarly, Compounds 1, 2, and 3 were used to functionalize 
a CM5 sensorchip surface after activation with a mixed solution of EDC-NHS. After injections of the 
different compounds, an increase of the immobilization level (in Resonance Unit) has been observed in 
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the sensorgrams as a clear signal of covalent attachment of these compounds to the activated carboxylic 
acid surface via amide linkages (data not shown). An immobilization level of 793, 961.5, and 848 RU 
has been obtained for compounds 1, 2 and 3, respectively. This validates this chemical strategy of 
"building block" production with this type of spacer allowing functional test of the carbohydrate unit in 
SPR analysis before getting to the expensive and time consuming chemical step assembly of 
multivalent dendrimeric compounds. These functionalized surfaces were used to study the binding 
process with the ECD of DC-SIGN in a flow mode. 
 
Surface plasmon resonance Binding assays.  
Binding assays were performed using increasing concentration of DC-SIGN ECD ranging from 0.1 
µM to 100 µM. These solutions of lectin were injected over the functionalized surfaces. The interaction 
profile of DC-SIGN ECD (figure 1) with the functionalized surfaces is indicative of a rapid association 
and dissociation processes (high kon and koff) and of a weak affinity of DC-SIGN ECD for the 
monosaccharide derivatives used here, compounds 1 and 2. This is in accord with the previously 
reported affinity for mannose of the DC-SIGN CRD in the milli-molar  range. (12) By contrast, the 
surface functionalized with the control compound 3 only showed a small non specific response 
presenting same RU level as observed on a surface without any functionalization (data not shown). This 
background interaction obtained with the control surface was subtracted from the signals obtained with 
surfaces functionalized with compounds 1 and 2. (Figure 1). 
An analysis of these curves by representation of DC-SIGN ECD concentration against the steady state 
response level (Req) observed for each functionalized surface showed a similar behavior for both types 
of surfaces (functionalized, at an equivalent density, with mannose conjugate linked at position 6 or at 
the anomeric position) (Figure 2). Because of the weak affinity observed for these carbohydrate-protein 
interactions the saturation curve did not present a maximum because it was not possible to reach the 
saturation situation in the concentration range used for the DC-SIGN ECD. To get access to a Kd would 
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require high amount of DC-SIGN ECD and at a concentration in the millimolar range that may not be 
accessible for solubility reason. Here we have access to the ascending part of the saturation curve. In 
case of marked difference in affinity of DC-SIGN ECD for both type of modified mannose, the change 
in Kd will be reflected not in the value of the maximum plateau reached but rather in position and 
evolution of the ascending part of the saturation curve. Here, figure 2 shows that there is no significant 
difference between the glycoconjugates 1 and 2. 
Our basic interest was centered to have a qualitative comparison of both surfaces to determine if both 
positions in the mannose ring (anomeric position and position 6) were accessible to be used as a focal 
point for linkage of this carbohydrate in order to prepare glycoconjugates and finally multivalent 
systems. This SPR analysis demonstrated that both position were appropriate to be used as points of 
functionalization to generate glycoconjugates and it is also possible to say that position 6, as can be 
observed in figure 2, is a good or even better than the anomeric position which is usually used to 
prepare carbohydrates conjugates. 
 
CONCLUSIONS 
In this work we have prepared two mannosyl conjugates at different positions, position 6 and position 
1 or anomeric position of the carbohydrate. With these conjugates, a CM5 chip surface of a biosensor 
was functionalized to create a carbohydrate surface to study the interaction with the tetrameric ECD of 
DC-SIGN. The analysis of the obtained sensorgrams showed that this binding process was fast and 
weak. In fact, for the concentration of protein used, it was not possible to reach the saturation and 
therefore, a quantitative calculation of Kd was not accessible. However, an important feature of this 
binding process with the lectin DC-SIGN was demonstrated for the first time; functionalization of 
mannose at position 6 is a very good alternative, as good as glycoconjugates functionalized at the 
anomeric position, to prepare glycoconjugates .  
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This fact opens new possibilities in the design of ligands for this receptor. The introduction of 
selected hydrophobic groups at the anomeric position of the reducing end of the corresponding 
carbohydrate can be envisaged. These hydrophobic groups could establish contact with hydrophobic 
residues present in the carbohydrate recognition domain and increase the affinity of these ligands for 
the receptor. Introduction of linkers at position 6 will allow the preparation of glycoconjugates with 
these ligands without lost of activity and also, will allow using them to prepare the corresponding 
multivalent systems to interact with DC-SIGN. 
 
LIST OF ABBREVIATIONS 
CRD   Carbohydrate Recognition Domain 
DC-SIGN   Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin 
DIC   Diisopropylcarbodiimide 
ECD   Extra Cellular Domain 
EDC   N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide 
EDTA   Ethylenediaminetetraacetic acid 
HOBt   1-Hydroxybenzotriazole 
ICAM   InterCellular Adhesion Molecule 
NHS   N-hydroxysuccinimide 
RU   Response Units 
SPR Surface Plamon Resonance 
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Figure Legends 
Figure 1. Sensorgrams corresponding to the injection of different concentrations of DC-SIGN ECD 
with surfaces functionalized with compound 1 (A) and compound 2 (B). The concentrations used were 
0.1, 0.2, 0.4, 0.8, 1.55, 3.1, 6.2, 12.5, 25, 50 and 100 µM. 
 
Figure 2. Representation of steady states response level (Req) for surfaces functionalized with 
glycoconjugates 1 (filled diamond) and 2 (filled square) as a function of DC-SIGN ECD concentration. 
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